Literature DB >> 8648808

Micropenis secondary to growth hormone deficiency: does treatment with growth hormone alone result in adequate penile growth?

J B Levy1, D A Husmann.   

Abstract

PURPOSE: Congenital growth hormone deficiency is associated with aberrant androgen physiology and micropenis. We investigated whether treatment with growth hormone alone is adequate to restore normal phallic growth.
MATERIALS AND METHODS: In all patients the diagnosis was isolated growth hormone deficiency and micropenis, and growth hormone was the only therapy. Stretched penile length, and somatic height and weight measurements were available from diagnosis through puberty for all patients.
RESULTS: Eight patients diagnosed with isolated congenital growth hormone deficiency and micropenis were treated and evaluated. Mean z-score (number of standard deviations below mean stretched penile length) at diagnosis was -4.25 (range 3.1 to -6.6) with -2.5 representing micropenis. In adulthood mean final stretched penile length z-score was -1.73 (range -0.91 to -2.66). Seven of the 8 patients (87.5%) had stretched penile length within normal range.
CONCLUSIONS: Our findings suggest that growth hormone therapy alone can result in normal phallic size in patients with micropenis secondary to isolated congenital growth hormone deficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648808     DOI: 10.1016/s0022-5347(01)66003-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  The child with micropenis.

Authors:  P S Menon; U A Khatwa
Journal:  Indian J Pediatr       Date:  2000-06       Impact factor: 1.967

Review 2.  Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions.

Authors:  Kerry L Hull; Steve Harvey
Journal:  Int J Endocrinol       Date:  2014-12-15       Impact factor: 3.257

3.  Effects of combined growth hormone and testosterone treatments in a rat model of micropenis.

Authors:  Jin Kyu Oh; Young Jae Im; Kwanjin Park; Jae-Seung Paick
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.